Dr. Helen Heslop elected to the National Academy of Medicine
Election to the National Academy of Medicine recognizes outstanding professional achievement and commitment to service.
Read MoreElection to the National Academy of Medicine recognizes outstanding professional achievement and commitment to service.
Read MoreThis study shows that this therapy can effectively get to the tumor, and the addition of C7R safely augments antitumor activity.
Read MoreNon-Hodgkin’s lymphoma patient Matt Rea flew to Houston to receive CD19 CAR-T cells from his identical twin brother Will Rea.
Read MoreThe HEROS 2.0 trial showed that this therapeutic approach is safe and is associated with clinical benefit.
Read MoreA first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.
Read MoreThe findings support further assessing this approach to treat aggressive blood cancers and ultimately improve outcomes in patients.
Read MoreBaylor College of Medicine researchers extend the life and effectiveness of off-the-shelf, cancer-fighting immune T cells.
Read MoreCAR-T cell therapy has been used to treat Hodgkin lymphoma with remarkable success for the first time in an early phase clinical trial.
Read MoreClinical trial of novel personalized CAR T cell immunotherapy provides clues into what mediated exceptional patient recovery.
Read MoreFrom the Labs celebrates Baylor College of Medicine’s Women of Science.
Read More